| Sep 12 |
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
|
| Aug 29 |
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 28 |
Favourable Signals For Immuneering: Numerous Insiders Acquired Stock
|
| Aug 7 |
Immuneering reports Q2 results
|
| Aug 6 |
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Jul 31 |
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
|
| May 29 |
Immuneering to Present at the Jefferies Global Healthcare Conference
|
